Pemvidutide vs Survodutide
How Pemvidutide and Survodutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Pemvidutide and Survodutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Pemvidutide vs Survodutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Pemvidutide | Survodutide |
|---|---|---|
| What it is | Synthetic peptide dual agonist of the GLP-1 and glucagon receptors | Synthetic peptide dual agonist of the glucagon and GLP-1 receptors (once-weekly, subcutaneous) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Metabolic dysfunction-associated steatohepatitis (MASH); Obesity; Alcohol use disorder; Alcohol-associated liver disease | Weight loss / obesity; MASH / MASLD (fatty-liver disease); Type 2 diabetes with overweight or obesity |
| US regulatory status (2026) | investigational (as of Jul 2026) | investigational (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 24 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Human randomized trials provide a useful short-term safety picture, with gastrointestinal effects such as nausea, vomiting, diarrhea and constipation most prominent. IMPACT reported few discontinuations due to adverse events through 24 weeks, but Phase 2 trials cannot establish the safety of longer or wider use. Pemvidutide remains investigational. | Survodutide has real human safety data, which sets it apart from most research peptides. The most common side effects in trials were gastrointestinal — nausea, vomiting, diarrhea and constipation — mostly mild to moderate and tied to how fast the dose was raised. Slow dose titration reduced them. Long-term safety and heart-outcome data are still being gathered in the phase 3 program. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.